How many cosentyx vials are used per injection?

How many Cosentyx vials are used per injection?

For standard adult dosing, a single Cosentyx injection uses either one 150 mg/mL prefilled syringe or pen, or two 75 mg/0.5 mL prefilled syringes or pens when aiming for a higher dose. Vials are only available in 150 mg/mL size and are intended for healthcare provider administration rather than self-injection.

Why do providers sometimes combine multiple units?

Providers use two 75 mg units to reach 150 mg or two 150 mg units to reach 300 mg. This is done to cover loading doses or maintenance regimens for conditions like psoriatic arthritis and ankylosing spondylitis. The company lists these options on its prescribing information.

When does the 150 mg vial become necessary?

The 150 mg vial is needed when a clinic chooses liquid-for-injection vials over pens or syringes. Clinics use it for patients who require 150 mg or 300 mg doses. Clinics also use vials when pen or syringe prices are higher under certain insurance plans.

Can biosimilars enter before patent expiry?

Cosentyx (secukinumab) has no approved biosimilars in the U.S. as of 2025. Its primary composition-of-matter patent expires in 2029. The company has filed several secondary patents on formulations and methods of use that could push exclusivity further. [1]

Why are companies challenging this patent?

Companies are challenging Cosentyx's patent family because high annual sales—over $6 billion in 2024—make any early entry attractive. The company has already faced biosimilar notifications from competitors such as Sandoz and Samsung Bioepis. Notifications begin five years before actual entry. [2]

When does exclusivity expire?

Exclusivity expires at the end of 2029. Secondary patents on formulation and dosing regimens could extend market protection until 2032 or 2033. Companies may delay entry through litigation rather than straight entry before 2029. [3]

DrugPatentWatch.com